IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1417 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
 » Next article
 » Previous article 
 » Table of Contents
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (222 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
   Abstract
   Introduction
   Materials and Me...
   Results
   Discussion
   Acknowledgments
   References
   Article Figures
   Article Tables

 Article Access Statistics
    Viewed7199    
    Printed232    
    Emailed4    
    PDF Downloaded225    
    Comments [Add]    
    Cited by others 9    

Recommend this journal

 


 
RESEARCH PAPER
Year : 2006  |  Volume : 38  |  Issue : 5  |  Page : 350-354
 

In vivo and in vitro effects of the Canova medicine on experimental infection with Paracoccidioides brasiliensis in mice


1 Department of Clinical Analyses, State University of Maringa, Brazil
2 Department of Pharmacy and Pharmacology, State University of Maringa, Brazil

Date of Submission20-Jul-2006
Date of Decision31-Jul-2006
Date of Acceptance04-Aug-2006

Correspondence Address:
RKN Cuman
Department of Pharmacy and Pharmacology, State University of Maringa
Brazil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.27704

Rights and Permissions

  Abstract 

Objective: To evaluate the in vivo and in vitro activity of Canova in experimental infection with Paracoccidioides brasiliensis. Materials and Methods: Mice infected with P. brasiliensis were treated with Canova for 17 weeks. Follow-up measures included the determination of total antibodies, global and differential leukocyte counts. Further, nitric oxide production was determined by adding macrophage cultures to different concentrations of Canova in the presence or absence of P. brasiliensis. Results: The data revealed the protective effect of Canova in P. brasiliensis- infected animals. A higher nitric oxide production was found in the Canova- treated cultures. Conclusion: These data suggest that Canova activates the macrophages by a way that depends, at least in part, on nitric oxide.


Keywords: Immunomodulator, macrophage activation, systemic mycosis.


How to cite this article:
Takahachi G, Maluf M, Svidzinski T, Dalalio M, Bersani-Amado C A, Cuman R. In vivo and in vitro effects of the Canova medicine on experimental infection with Paracoccidioides brasiliensis in mice. Indian J Pharmacol 2006;38:350-4

How to cite this URL:
Takahachi G, Maluf M, Svidzinski T, Dalalio M, Bersani-Amado C A, Cuman R. In vivo and in vitro effects of the Canova medicine on experimental infection with Paracoccidioides brasiliensis in mice. Indian J Pharmacol [serial online] 2006 [cited 2021 Dec 7];38:350-4. Available from: https://www.ijp-online.com/text.asp?2006/38/5/350/27704



  Introduction Top


The Canova® (Canova of Brazil) method medicinal product is composed of 5 traditional homeopathic substances: Aconitum, Arsenicum album , Bryonia alba , Lachesis muta and Thuya occidentalis . This product has been used for patients with AIDS and cancers, where the immunological system is depressed.[1]

Clinical and experimental observations demonstrate that the Canova medicine promotes an improvement in concomitant infectious and inflammatory conditions, apart from the reduction and regression of tumour[1],[2] in some cases. Experimental data demonstrates that the mechanism of action of the Canova compound is probably due to the increase in the immune response through macrophage activation.[3] Other actions such as a decrease in the production of the tumour necrosis factor-a (TNF-a),[3] stimulation of leishmanicidal activity and nitric oxide (NO) production in macrophages[4] are also attributed to Canova.

Paracoccidioidomycosis (PCM) is a progressive, systemic fungal disease of granulomatous origin. It affects mainly the lungs, ganglions and mucosa, as well as other organs and systems with varying clinical signs and symptoms.[5] The disease is geographically limited to Latin American countries and some regions of Brazil are considered as reservoirs and endemic.[6],[7]

In PCM, the effective and protective response of the host depends primarily on cell-mediated immunity, with neutrophils and macrophages playing an important role in phagocytosis.[8] High levels of anti P. brasiliensis antibodies are associated with the most severe forms of the disease.[9] The immunological dysfunction, associated with PCM, is characterised as a specific antigen defect of the cellular immunity which is reversible with the treatment of the disease and is possibly related to a Th2 standard immune response during the active disease.[10]

The analysis of the cytokines production and immunopathological characteristics, in resistant and susceptible mice, indicate that resistance to P. brasiliensis infection is associated with an early activation of immune mechanisms which leads to a Th1 response. Susceptibility is related to the early production of mediators which inhibit the production of interferon gamma (IFN-g), which suppress the progress of the protective Th1 immunity.[11]

The importance of the immunoregulatory effects of the cytokines in the resistance mechanism of PCM was demonstrated by in vitro and in vivo studies. It was shown that IFN-g produced during the cellular immune response activates macrophages which are important in controlling P. brasiliensis infection, thus proving the efficacy of the immunomodulatory therapy.[12],[13]

In the present study, the effect of the Canova medicine on the evolution of experimental P. brasiliensis infection and on the activation of infected macrophage in vitro was evaluated.


  Materials and Methods Top


Fungus

The isolate P. brasiliensis Pb18 from the Pathology Department, Medical Faculty, State University of Sao Paulo (UNESP - Botucatu Campus) was used. The yeast cells were cultured in YPD (Yeast extract, Casein-peptone, Dextrose) semi-solid medium at 35ºC for 7 days. To prepare the inoculum, the cells were washed 3 times with sterile phosphate buffer solution (PBS) of pH 7.2. The cell viability was determined, using the Janus Green vital stain. Cultures with a minimum of 80% viability were used and the concentration adjusted by counting in a Neubauer chamber.

Animals

Male Swiss albino mice, 4-6 weeks' old, from the Central Animal Facilities of the State University of Maringa were used. The animals were divided into 3 groups of 50 mice each: Canova (infected and Canova treated); PCM (infected but not treated) and Control (not infected and not treated). The mice were infected with 0.5 ml of the fungus suspension at a concentration of 1.0 X 10 7 cells/ml (5 X 10 6 yeast cells) i.p.[14] During the experimental period, the animals were housed under standard laboratory conditions with ad libitum water and balanced food. The experiments were approved by the University Ethics Committee of the State University of Maringα.

Treatment

The Canova® medicine was administered intragastrically (0.2 ml/day).[4] The treatment was started on the same day of induction of infection and maintained for 17 weeks.

Treatment evaluation

During weeks 4, 6, 10, 14 and 17 after the infection was induced, 10 mice from each group were anaesthetised (50 mg/kg ketamine hydrochloride and 50 mg/kg thiazine hydrochloride, i.p.) and blood samples collected to determine the number of total and differential leukocytes and the total antibody titre against P. brasiliensis . A Neubauer chamber was used for the global leukocyte count, while the differential count was done by optical microscopy, using blood smears stained with the Leishman stain. The serum levels of specific antibodies were determined by the ELISA method, using P. brasiliensis culture filtrate as the antigen.[7] Commercial antimouse total immunoglobulin peroxidase conjugate (Sigma®) was used to detect the antigen-antibody reaction.

Macrophage culture

Peritoneal cells were extracted from healthy mice, by washing the peritoneal cavity with 5 ml of cold PBS. After that, the cells were re-suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 40 µg/ml gentamicin, 20 mM HEPES, 2.5x10 -5sub M 2-mercapto-ethanol. For the macrophage culture, 1 ml of a 2 X 10 6 cells/ml suspension was cultured in 24 well plates (CORNING®) for 2 h at 37ºC and 5% CO 2 . After incubation, the culture supernatants were aspirated and the non-adherent cells removed. The monolayer of macrophages was incubated again, at 37ºC and 5% CO 2 , for 21 h 3sub with complete RPMI containing 10%, 20% or 40% of the Canova medicine. Culture without Canova was used as control.

Co-culture of macrophage and P. brasiliensis

After the incubation period with Canova, the supernatants of the cultures were discarded and the macrophages challenged against 4 X 10 4sub (1:50 fungus:macrophages) yeast cells of P. brasiliensis suspended in RPMI supplemented with 10% fresh mice serum. The co-cultures were re-incubated at 37ºC and 5% CO 2 for 4 h. After incubation, the culture supernatants were removed and the nitric oxide level estimated. Cultures containing P. brasiliensis yeast cells or non-treated macrophages plus yeast cells were used as controls.

Nitric oxide (NO) determination

The NO 2 concentration, in the culture supernatants, was used as an indicator of NO generation, and was measured using the Griess reagent (1% sulphanilamide, 0.1% naphthylenediamine, 2.5% H 3 PO 4 ).[15] Plates of 96 wells (CORNING®) were used and 50 µl of the supernatant was added to the same volume of the Griess reagent and incubated at room temperature for 10 min. After incubation, the absorbance was determined in a microplate reader (FL 600 BIO-TEK®) using 530 nm filter, against a blank (culture medium and the Griess reagent), under the same conditions as described before. The results were expressed as µM of NO 2 , using a sodium nitrite standard curve. All determinations were made in triplicate.

Statistical analysis

The program GraphPad Prism® (version 3.0, GraphPad Software, Inc.) was used for the statistical analysis. The results are expressed as mean±SEM. The groups difference were analysed in each week using non-parametric analysis of variance (one-way ANOVA), followed by the Tukey test or Kruskal-Wallis test, followed by the Dunns test, for multiple comparisons. The level of significance used was 0.05.


  Results Top


Antibody level

P. brasiliensis
infection induced a significant increase in antibody level after the 6th week of fungal inoculation. A significant reduction of anti P. brasiliensis antibody was seen in the Canova-treated group compared to the PCM group in the 10th ( P <0.01), 14th and 17th ( P <0.05) weeks. [Figure - 1]

Global and differential leukocyte count

The infected, untreated mice initially presented a reduction in total leukocyte count in the 4th week of infection ( P <0.05), due to the reduction in mononuclear cells ( P <0.01), and lymphocyte count ( P <0.05). In the succeeding weeks, the leukocyte count increased gradually with a peak during the 10th week of infection ( P <0.001), with an increase in polymorphonuclear ( P <0.001) and mononuclear cells ( P <0.001). For the Canova-treated infected animals, this increase started in the 4th week ( P <0.01), with a peak during the 6th week after infection ( P <0.001). This increase was associated with an elevation in mononuclear cells ( P <0.001), such as lymphocytes and monocytes. [Table - 1][Table - 2]

Nitric oxide

The Canova medicine caused an increase in nitric oxide in the macrophage culture supernatant, with all the concentrations tested, without any significant difference between them.

The culture with Canova promoted a higher increase ( P <0.001) in nitric oxide, than P. brasiliensis alone ( P <0.05). The supernatant of the cultures containing P. brasiliensis and Canova in the tested concentrations were also determined and the concentrations were close to 1.0 µM. [Figure - 2]


  Discussion Top


In PCM, the response of the host to the infective agent occurs primarily through cell mediated immunity. Neutrophils and macrophages have an important role in the phagocytosis of PCM.[8] However, in this systemic mycosis, depressed cell mediated immunity is commonly observed.[16] Antifungal therapy, combined with an immunomodulator, might be efficient in the treatment of this disease.[12] On the other hand, many works have been carried out to study the control of the PCM using antifungal drugs, so this effect is well estabilished. In this way, we did not use, in this protocol, an antifungal-treated group. Thus, the effect of the Canova medicine in experimental murine PCM was studied.

The results of the present study revealed a significant decrease in total leukocytes, with a significant decrease in the lymphocyte count in the 4th week of PCM infection. In the 10th week of infection, a significant increase in the total leukocyte count was observed in the PCM-infected group, while in the Canova-treated animals, this elevation was earlier, starting in the 4th week and peaking in the 6th week, with an increase in the number of mononuclear cells.

The global and differential leukocyte counts of the Canova-treated animals were similar to those of the uninfected animals (control group) in the majority of the weeks (14th and 17th) studied. These facts indicate that the Canova medicine may already be acting in the first week of treatment, possibly favourably affecting the immunological response. This is reflected in the significant reduction of antibody level, while the positive control group exhibited high levels of the same from the 10th week after infection, persisting in the 17th week. These results are in accord with an increase in the number of mononuclear cells, with a peak at the 10th week of infection. This increase might reflect an elevation of B lymphocytes, since there is an increase in the polyclonal B lymphocytes in more severe cases of PCM.[9]

As high levels of antibodies are associated with more severe forms of the disease and used as indicator of clinical recurrence,[9] the present results suggest that PCM infection was less severe in the Canova-treated group.

A significant increase in NO production was observed in the macrophage culture incubated with P. brasiliensis, compared to those without the fungus. These findings indicate probable macrophages and involvement of the nitric oxide pathway. Gonzalez et al ,[17] also observed an increase in the fungicidal capacity of peritoneal macrophages in mice activated with IFN-g on conidia and yeast cells of P. brasiliensis , and that the incubation of these cells with nitric oxide synthase inhibitors reverted this effect, suggesting that the increased fungicidal activity could be mediated by nitric oxide production.

In our experiments, supernatants of macrophage cultures, infected or not, and incubated with Canova presented higher NO concentrations than the control without Canova. Our data indicate that Canova has a potential for macrophage activation as also suggested by Piemonte & Buchi.[3]

One of the characteristics of activated macrophages is the increase in NO production.[18] NO possess antimicrobial activity; through reaction with super oxides, peroxy nitrite is produced, which is cytotoxic and important for the cellular immunity.[19],[20] Many in vitro and in vivo studies have demonstrated a direct correlation between the NO production and the antimicrobial activity of the macrophages in the presence of various microorganisms, such as Leishmania amazonensis,[4] Histoplasma capsulatum,[21] Trypanosoma cruzi [22] and Schistosoma mansoni .[23]

The present results suggest that the control of the infection may be due to the activation of the cellular response in the animals treated with Canova. When the macrophages are activated, they may have additional effects on the fungus, through the release of pro-inflammatory cytokines. Further studies are needed to know more about the antimicrobial activity of Canova.


  Acknowledgments Top


This work was partially supported by Conselho Nacional de Desenvolvimento Cientνfico e Tecnológico. We thank Dr. Roberto Piraνno for providing the Canova medication samples. We are also grateful to Juarez Antonio da Silva, Sandra Regina Corbelo Pereira and Eliana Guilhermetti for their technical assistance.

 
  References Top

1.Sasaki MGM, Mariano FC, Gurgel LP, Probst S. Estudo clνnico randomizado placebo controlado para avaliar a eficαcia e seguranηa do Mιtodo Canova® na terapκutica de pacientes portadores de HIV/Aids em uso de anti-retrovirais. Braz J Infect Dis 2001;5:58.  Back to cited text no. 1    
2.Sato DYO, Wal R, Oliveira CC, Cattaneo RII, Malvezzi M, Garbado J, et al . Histopathological and immunophenotyping studies on normal and sarcoma 180-bearing mice treated with a complex homeopathic medication. Homeopathy 2004;94:26-32.  Back to cited text no. 2    
3.Piemonte MR, Buchi DF. Analysis of IL-2, IFN-g and TNF-a production, a5b1 integrins and actin filaments distribution in peritoneal mouse macrophages treated with homeopathic medicament . J Submicrosc Cytol Pathol 2002;34:255-63.  Back to cited text no. 3    
4.Pereira WKV, Lonardoni MVC, Grespan R, Caparroz-Assef SM, Cuman RKN, Bersani-Amado CA. Immunomodulatory effect of Canova medication on experimental Leishmania amazonensis infection. J Infect 2005;51: 157-64.  Back to cited text no. 4    
5.Mendes RP. The Gamut of Clinical Manifestations. In: M Franco MS, Lacaz A, Restrepo-Moreno G, Del Negro, editors. Paracoccidioidomycosis. Boca Raton: CRC Press; 1994. p. 233-58.  Back to cited text no. 5    
6.Coutinho ZF, Silva D, Lazera M, Petri V, Oliveira RM, Sabroza PC, Wanke B. Paracoccidioidomycosis mortality in Brazil (1980-1995). Cad Saúde Pública 2002;18:1441-454.  Back to cited text no. 6    
7.Maluf MLF, Pereira SRC, Takahachi G, Svidzinski TIE. Prevalκncia de paracoccidioidomicose-infecηγo determinada atravιs de teste sorológico em doadores de sangue na regiγo Noroeste do Paranα, Brasil. Rev Soc Bras Med Trop 2003;36:11-6.  Back to cited text no. 7    
8.Popi AF, Lopes JD, Mariano M. GP 43 from Paracoccidioides brasiliensis inhibits macrophage functions. An evasion mechanism of the fungus. Cell Immunol 2002;218:87-94.  Back to cited text no. 8    
9.Calich VLG, Vaz CAC, Burger E. Immunity to Paracoccidioides brasiliensis infection. Res Immunol 1998;149:407-17.  Back to cited text no. 9    
10.Benard G, Hong MA, Del Negro GM, Batista L, Shinakanai-Yassuda MA, Duarte AJ. Antigen-specific immunosuppression in paracoccidioidomycosis. Am J Trop Med Hyg 1996;54:7-12.  Back to cited text no. 10    
11.Calich VLG, Kashino SS. Cytokines produced by susceptible and resistant mice in the course of Paracoccidioides brasiliensis infection. Braz J Med Biol Res 1998;31:615-23.  Back to cited text no. 11    
12.Cano LE, Kashino SS, Arruda C, Andre D, Xidieh CF, Singer-Vermes LM, et al . Protective role of Gamma Interferon in Experimental pulmonary paracoccidioidomycosis. Infect Immun 1998;66:800-6.  Back to cited text no. 12    
13.Brummer E, Hanson LH, Stevens DA. Gamma-Interferon activation of macrophages for killing of Paracoccidioides brasiliensis and evidence for nonoxidative mechanisms. Int J Immunopharmacol 1988;10:945-52.  Back to cited text no. 13    
14.Singer-Vermes LM, Caldeira CB, Burger E, Calich VLG. Experimental murine paracoccidioidomycosis: relationship among the dissemination of the infection, humoral and cellular immune responses. Clin Exp Immunol 1993;94:75-9.  Back to cited text no. 14    
15.Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 1988;141:2407-12.  Back to cited text no. 15    
16.Camargo ZP, Franco, MF. Current knowledge on pathogenesis and immunodiagnosis of paracoccidioidomycosis. Rev Iberoam Micol 2000; 17: 41-8.  Back to cited text no. 16    
17.Gonzalez A, Gregori W, Velez D, Restrepo A, Cano LE. Nitric oxide in the fungicidal mechanism of gamma interferon-activated murine macrophages against Paracoccidioides brasiliensis conidia. Infect Immun 2000;68: 2546-52.  Back to cited text no. 17    
18.MacMicking J, Xie Q, Nathan C. Nitric Oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.  Back to cited text no. 18    
19.Barbuto JA. Imunidade natural e inflamaηγo. In: Calich V, Vaz C, editors. Imunologia . Rio de Janeiro: Revinter; 2001. p. 179-93.  Back to cited text no. 19    
20.Jancar S. Imunidade natural e inflamaηγo. In: Calich V, Vaz C, editor. Imunologia . Rio de Janeiro: Revinter; 2001. p. 11-30.  Back to cited text no. 20    
21.Lane TE, Otero GC, Wa-Hsieh B, Howard DH. Expression of inducible nitric oxide synthase by stimulated macrophages correlates with their antihistoplasma activity. Infect Immun 1994;62:1940-5.  Back to cited text no. 21    
22.Norris KA, Schirimpf JE, Flynn JL, Morris Jr SM. Enhancement of macrophages microbicidal activity: supplemental arginine and citrulline augment nitric oxide production in murine peritoneal macrophages and promote intracellular killing of Trypanossoma cruzi . Infect Immun 1995;63: 2793-6.  Back to cited text no. 22    
23.James SL, Glaven J. Macrophage citotoxicity against schistosomula of Schistosoma mansoni involved arginine-dependent production of reactive nitrogen intermediates. J Immunol 1989;143:4208-12.  Back to cited text no. 23    


    Figures

[Figure - 1], [Figure - 2]

    Tables

[Table - 1], [Table - 2]

This article has been cited by
1 Treatment with at homeopathic complex medication modulates mononuclear bone marrow cell differentiation
De Freitas Buchi, D., Cesar, B., Abud, A.P.R., De Oliveira, C.C., Cardoso, F., Bernardi, R.P.D., Guimarães, F.S.F., Gabardo, J.
Evidence-based Complementary and Alternative Medicine. 2011; 2011(art ): 212459
[Pubmed]
2 Canova medication modifies parasitological parameters in mice infected with Trypanosoma cruzi
Pupulin, A.R.T., Marques-Araujo, S., Toledo, M.J.O., Gomes, M.L., Takejima, E., Cuman, R.K.N., Bersani-Amado, C.A.
Experimental Parasitology. 2010; 126(4): 435-440
[Pubmed]
3 Canova medication modifies parasitological parameters in mice infected with Trypanosoma cruzi
Aurea Regina Telles Pupulin,Silvana Marques-Araujo,Max Jean Ornelas Toledo,Mônica Lúcia Gomes,Edilson Takejima,Roberto Kenji Nakamura Cuman,Ciomar Aparecida Bersani-Amado
Experimental Parasitology. 2010; 126(4): 435
[Pubmed] | [DOI]
4 Effects of herbal medicinal formulas on suppressing viral replication and modulating immune responses
Liao, H.-F., Lu, M.-C., Chang, H.-C., Wei, C.-C., Kao, C.-H., Chen, Z.-H., Huang, C.-C., Li, C.
American Journal of Chinese Medicine. 2010; 38(1): 173-190
[Pubmed]
5 Treatment with at Homeopathic Complex Medication Modulates Mononuclear Bone Marrow Cell Differentiation
B. Cesar, A. P. R. Abud, C. C. de Oliveira, F. Cardoso, R. P. D. Bernardi, F. S.F. Guimaraes, J. Gabardo, D. de Freitas Buchi
Evidence-based Complementary and Alternative Medicine. 2009;
[VIEW] | [DOI]
6 Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication
Fernando SF Guimarães, Ana PR Abud, Simone M Oliveira, Carolina C Oliveira, Beatriz César, Lucas F Andrade, Lucélia Donatti, Juarez Gabardo, Edvaldo S Trindade, Dorly F Buchi
BMC Cancer. 2009; 9(1)
[Pubmed] | [DOI]
7 Stimulation of lymphocyte anti-melanoma activity by co-cultured macrophages activated by complex homeopathic medication
Guimarães, F.S.F., Abud, A.P.R., Oliveira, S.M., Oliveira, C.C., César, B., Andrade, L.F., Donatti, L., Buchi, D.F.
BMC Cancer. 2009; 9(art 1471): 293
[Pubmed]
8 A review of immunomodulators with reference to Canova®
Smit, E., Oberholzer, H.M., Pretorius, E.
Homeopathy. 2009; 98(3): 169-176
[Pubmed]
9 Gene expression profiling of macrophages following mice treatment with an immunomodulator medication
Carolina Camargo de Oliveira, Simone Martins de Oliveira, Viviane M. Goes, Christian M. Probst, Marco Aurelio Krieger, Dorly de Freitas Buchi
Journal of Cellular Biochemistry. 2008; 104(4): 1364-1377
[Pubmed] | [DOI]



 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow